Search, analyze & compare

Company details

Akero Therapeutics Inc. is a biotechnology company focused on the development and commercialization of treatments for serious metabolic diseases. The company primarily aims to address non-alcoholic steatohepatitis (NASH), which is a severe form of non-alcoholic fatty liver disease marked by inflammation and liver cell damage. Akero Therapeutics leverages advanced scientific understanding of liver pathophysiology and medicinal chemistry to design and develop innovative therapeutics. One of their notable investigational drugs targets pathways involved in metabolic processes and immune regulation, with the potential to improve liver health and function. Operating at the intersection of biotechnology and healthcare, Akero Therapeutics contributes to a vital sector addressing unmet medical needs. The company’s research and development efforts are significant within the biomedical field, given the rising incidence of metabolic disorders globally. As such, Akero Therapeutics plays a critical role in pushing forward advancements in medical science aimed at enhancing patient outcomes in diseases lacking effective treatments.